DDInter1870 DDInter1008
Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as [levodopa]. Trihexyphenidyl was granted FDA approval on 13 May 1949.
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Trihexyphenidyl {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) causes {v} (Side Effect) Dry skin
Dry skin {u} (Side Effect) is caused by {v} (Compound) Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) resembles {v} (Compound) Biperiden
Biperiden {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) resembles {v} (Compound) Oxybutynin
Oxybutynin {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) palliates {v} (Disease) Parkinson's disease
Parkinson's disease {u} (Disease) downregulates {v} (Gene) ALAS1
ALAS1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) resembles {v} (Compound) Biperiden
Biperiden {u} (Compound) downregulates {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) palliates {v} (Disease) Parkinson's disease
Parkinson's disease {u} (Disease) is associated with {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) resembles {v} (Compound) Biperiden
Biperiden {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is downregulated by {v} (Compound) Ketoconazole
Trihexyphenidyl {u} (Compound) palliates {v} (Disease) Parkinson's disease
Parkinson's disease {u} (Disease) is associated with {v} (Gene) and {u} (Disease) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Trihexyphenidyl (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Ketoconazole (Compound)
Trihexyphenidyl (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Trihexyphenidyl (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Posaconazole (Compound) and Posaconazole (Compound) resembles Ketoconazole (Compound)
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ketoconazole (Compound)
Trihexyphenidyl (Compound) resembles Oxybutynin (Compound) and Oxybutynin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ketoconazole (Compound)
Trihexyphenidyl (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) downregulates ALAS1 (Gene) and ALAS1 (Gene) is upregulated by Ketoconazole (Compound)
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Ketoconazole (Compound)
Trihexyphenidyl (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is associated with CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ketoconazole (Compound)
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is downregulated by Ketoconazole (Compound)
Trihexyphenidyl (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is associated with DDIT4 (Gene) and Parkinson's disease (Disease) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Ketoconazole (Compound)